Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report

• Published in: Journal of medical case reports 2021-02, Vol.15 (1), p.72-72, Article 72
• Main Authors: Olsen, T Anders, Martini, Dylan J, Evans, Sean T, Goldman, Jamie M, Bilen, Mehmet Asim
• Format: Article
• Language: English
• Subjects: Adverse events and renal cell carcinoma; Aged; Antibodies, Monoclonal, Humanized; Axitinib; Blood; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Care and treatment; Case Report; Case reports; Combination therapy; Comparative analysis; Complications and side effects; Cyanosis; Cytochrome; Enzymes; FDA approval; Hemoglobin; Humans; Hypothyroidism; Hypoxia; Immunotherapy; Inhibitor drugs; Ipilimumab; Kidney cancer; Kidney Neoplasms - drug therapy; Laboratories; Male; Metabolites; Metastasis; Methemoglobinemia; Monoclonal antibodies; Mutation; Patients; Quality of life; Targeted cancer therapy; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A
• ISSN: 1752-1947; 1752-1947
• DOI: 10.1186/s13256-020-02637-w

Combination regimens that include immune checkpoint (ICI) and vascular endothelial growth factor (VEGF) inhibition have opened the door to new treatment opportunities for patients with metastatic renal cell carcinoma (mRCC). While these treatment options have provided improved tolerability and better outcomes compared to older regimens, many patients still experience a myriad of treatment-related adverse events. Given that these regimens were recently approved for mRCC, the complete side effect profile may not be fully elucidated yet. We report a case of a 73-year old White male with mRCC who was managed with an ICI-VEGF inhibitor combination regimen. He experienced a partial response (Fig. 1) but had side effects including symptomatic cyanosis diagnosed as methemoglobinemia which led to treatment discontinuation. Upon holding his therapy, his methemoglobinemia and cyanosis resolved. Combination VEGF-ICI therapy provide novel regimens for advanced solid tumor malignancies including mRCC. While shown to have improved efficacy in clinical trials, it is crucial that oncologists uncover the full side effect profile of these novel agents especially as their use becomes more standard in the management of advanced malignancies. To our knowledge, this is the first reported case of a patient experiencing symptomatic methemoglobinemia as an adverse event associated with a VEGF-ICI combination regimen. While the cause of this side effect is unclear, in this paper we attempt to elucidate a process that is in line with the mechanism of action of these therapies to explain how these agents, specifically the axitinib, could have caused the methemoglobin to rise to a symptomatic level.